- t2cure’s cell therapy is available through cooperating clinical centres
- t2cure cooperates with experienced partners in research and in the industry.
- t2cure's pipeline is built on clinical studies in cardiac and peripheral vascular indications
- t2cure is dedicated to the development of novel progenitor cell-based regenerative therapeutics.
Overview/Mission
t2cure is dedicated to the development of novel progenitor cell-based regenerative therapeutics to provide new treatment options to patients suffering from cardiac or peripheral vascular diseases.
t2cure is a biopharmaceutical company founded by Prof. Andreas M. Zeiher and Prof. Stefanie Dimmeler, both internationally renowned academic researchers at Frankfurt University. The founders of t2cure developed a therapeutic approach to effectively induce neo-vascularization and repair processes in ischemic tissue. The new therapeutics consist of autologous progenitor cells prepared from a patient’s own bone marrow. These progenitor cells have the potential to induce repair and healing processes in cardiac or peripheral tissues. The cells are administered via catheter into the coronary arteries of a diseased heart or into peripheral arteries of a diseased limb in a routine procedure.
t2cure is active in two therapeutic areas: cardiac diseases, with focus on myocardial infarction and chronic heart disease; and peripheral arterial diseases, with focus on thromboangiitis obliterans. More than 550 patients were treated with the progenitor cell-based therapy to date. The therapy is available to patients in Germany at specialized clinical centers.